The FDA recently approved Zepbound, a weekly injectable drug targeted to treat obesity. The medication contains tirzepatide, the same active ingredient that is also present in the diabetes drug Mounjaro.
People with obesity who took the highest dose of the drug lost 21 percent of their total body weight, according to a randomized-controlled trial published in the New England…

#fda#zepbound#mounjaro#cdc#glp1#ozempic